ReviewACS omega2023
Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges.
Review in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prevalence of Tinea pedis in military personnel: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Trial
- Article
- Oral isotretinoin for the treatment of dermatologic conditions other than acne: a case series.Dermatology reports · 2026Article
- Sand Quality on Portuguese Blue Flagged Beaches: Fungal and Faecal Contamination Across Two Bathing Seasons.Microorganisms · 2026Article
- Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.Archives of microbiology · 2026Review
- The Dangers of Misuse of Corticosteroid Drugs in Treating Superficial Fungal Infections: Presentation of a Case Series for Stricter Policy Regulation.Public health challenges · 2025Article
- Utility of MALDI-ToF MS for Recognition and Antifungal Susceptibility of Nannizzia, an Underestimated Group of Dermatophytes.Mycoses · 2025Article
- In vitro activity of nanoliposomal amphotericin B against terbinafine-resistant Trichophyton indotineae isolates.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Exploring the Diversity and Distribution of Medico-Veterinary Fungal Diseases in Africa: Harnessing a Multisectoral One Health Strategy for Cost-Effective Prevention and Preparedness.Journal of fungi (Basel, Switzerland) · 2025Review
- Development of nanospray loaded with ciclopirox for dermal fungus treatment: determination of pro-inflammatory interleukin IL-2 mRNA expression.BMC pharmacology & toxicology · 2025Article
- Article
- Antifungal potential of copper oxide nanoparticles againstCurrent medical mycology · 2025Article
- Evaluation of the antifungal activity of coconut oil/chitosan nanoparticles againstOpen veterinary journal · 2025Article
- Layer-by-Layer Biopolymer-Coated Deformable Liposomes-In Situ Gel: A Hybrid Strategy for Enhanced Ocular Delivery of Itraconazole: In Vitro and In Vivo Appraisal.Gels (Basel, Switzerland) · 2024Article
- Host-Pathogen Interaction and Resistance Mechanisms in Dermatophytes.Pathogens (Basel, Switzerland) · 2024Review
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Humans vs. Fungi: An Overview of Fungal Pathogens against Humans.Pathogens (Basel, Switzerland) · 2024Review
- Atypical and Unpredictable Superficial Mycosis Presentations: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most prevalent infection in the world is dermatophytosis, which is a major issue with high recurrence and can affect the entire body including the skin, hair, and nails. The major goal of this Review is to acquire knowledge about cutting-edge approaches for treating dermatophytosis efficiently by adding antifungals to formulations based on nanocarriers in order to overcome the shortcomings of standard treatment methods. Updates on nanosystems and research developments on animal and clinical investigations are also presented. Along with the currently licensed formulations, the investigation also emphasizes novel therapies and existing therapeutic alternatives that can be used to control dermatophytosis. The Review also summarizes recent developments on the prevalence, management approaches, and disadvantages of standard dosage types. There are a number of therapeutic strategies for the treatment of dermatophytosis that have good clinical cure rates but also drawbacks such as antifungal drug resistance and unfavorable side effects. To improve therapeutic activity and get around the drawbacks of the traditional therapy approaches for dermatophytosis, efforts have been described in recent years to combine several antifungal drugs into new carriers. These formulations have been successful in providing improved antifungal activity, longer drug retention, improved effectiveness, higher skin penetration, and sustained drug release.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.